RealTime Dynamix™: Rheumatoid Arthritis US Q2 2016 Spotlight

spotlight-bnr

RealTime Dynamix™: Rheumatoid Arthritis Q2

The RealTime Dynamix™: Rheumatoid Arthritis report series provides a detailed and timely look at current and future trends in the RA market, and the effects of the future shifting landscape. Through a survey of 100 US rheumatologists, the 2016 Q2 installment does a deep dive into the influence and restrictions of managed care on biologic/JAK prescribing.
Rheumatologists are in tune with the reimbursement and access environment and actively involved in their
patients’ coverage and managed care issues.

 

spotlight-v1-img-2

Of the time, rheumatologists first check formulary coverage and co-pay information before starting RA patients on biologics/JAK agents

Just under two-thirds of rheumatologists report that they are involved with payers as it relates to the use of biologics/JAKs at least on a weekly basis.

Managed care influence and pressure for biologic/JAK prescription is high and has a significant
impact on treatment decisions.

Cost/insurance is the most selected barrier to increased use across all biologics/ Xeljanz, but use of Xeljanz, Actemra and Cimzia are perceived by rheumatologists as the most restricted by managed care.

spotlight-txt-line

 

 

xeljan-img

Over half of all rheumatologists who believe that cost/reimbursement is a primary barrier for use of Xeljanz also think that plan coverage is the main issue.

Unaided, if cost/reimbursement were not an issue for Xeljanz,
rheumatologists said:
  • xl-img-1-newWould use more
    Xeljanz
  • xl-img-2Would use Xeljanz first-line
    prior after MTX failure

RealTime Dynamix: Rheumatoid Arthritis Q2 is the second installment of the 2016 report series focusing on current and anticipated future trends in the RA treatment landscape. For more information contact: [email protected]

2017-10-25T13:15:25+00:00